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Abstract
Drug hypersensitivity reactions (DHRs) in childhood are mainly caused by betalactam or non-betalactam antibiotics,
and non-steroidal anti-inflammatory drugs (NSAIDs). Laboratory tests for identifying children who are allergic to
drugs have low diagnostic accuracy and predictive value. The gold standard to diagnose DHR is represented by the
drug provocation test (DPT), that aims of ascertaining the causative role of an allergen and evaluating the tolerance
to the suspected drug. Different protocols through the administration of divided increasing doses have been
postulated according to the type of drug and the onset of the reaction (immediate or non immediate reactions).
DPT protocols differ in doses and time interval between doses. In this position paper, the Italian Pediatric Society
for Allergy and Immunology provides a practical guide for provocation test to antibiotics and NSAIDs in children
and adolescents.
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Introduction
Data on prevalence and incidence of drug hypersensitiv-
ity reactions (DHRs) are limited, especially in the
pediatric age and varies around the world [1]. About
10% of parents report that their children are allergic to
drugs [2]. In prospective studies conducted in children
and adolescents, the rate of adverse drug reactions was
10.9% in hospitalized children, 1.0% in outpatients, and
the hospitalizations rate for adverse drug reactions was
of 1.8% [3]. Mild delayed cutaneous reactions including
maculopapular rashes (20–80%) and urticaria/angio-
edema (20–30%) are common reactions in children.
Anaphylaxis and severe cutaneous reactions are rare, al-
though they may occur up to 10% of patients with sus-
pected drug reactions [4]. Serum Sickness-Like
Reactions (SSLRs) are less common (0.02 to 0.2% of
children) and mostly related to first generation cephalo-
sporins [5]. DHRs are classified as immediate or nonim-
mediate/delayed reactions. Immediate reactions typically
occur within one hour after the last drug administration
and they are often caused by direct mast cell activation
or IgE-mediated hypersensitivity. Delayed reactions
occur from 1 h after drug administration and may result
from antigen-specific IgG production, complement acti-
vation or a T-cell mediated response [6–8]. Reactions oc-
curring between 1 and 6 h after the last drug intake are
called accelerate and can be caused both by an
IgE-mediated and T-lymphocyte mediated response.
There is an overlap between accelerate and delayed reac-
tions. Immediate drug reactions may manifest as isolated
mild symptoms (urticaria, angioedema, coughing, con-
junctivitis, rhinitis, nausea, vomiting, diarrhea, abdom-
inal pain), severe respiratory symptoms (bronchospasm,
dyspnea), and rarely as anaphylaxis [9]. The most com-
mon mild cutaneous non-immediate reactions are macu-
lopapular or morbilliform exanthema, eczema, delayed
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urticaria and/or angioedema [10]. They appear from 6 h
to 5 days after starting a course of treatment [1, 6, 8, 11,
12]. Delayed reactions can onset at any time after the
initial drug administration, from 1 h to several weeks
after, and can affect individual organs or systems (neph-
ritis, pneumoniae, haemolytic anaemia, cytopenia, hepa-
titis, vasculitis and serum sickness) with or without
cutaneous symptoms. Delayed severe cutaneous adverse
reactions (SCAR) include erythema multiforme major
(EMM), generalized acute exanthematous pustulosis
(AGEP), drug eruption with eosinophilia and systemic
symptoms (DRESS), Stevens-Johnson syndrome (SJS)
and toxic epidermal necrolysis (TEN). A history of
SCAR or SSLRs contraindicates the performance of drug
provocation test (DPT). However, some children with
SSLR to amoxicillin who tolerated DPT [13, 14] and pa-
tients with SSLR to cefaclor who tolerated other cepha-
losporins are reported [14]. In childhood, antibiotics,
mainly penicillins, and non-steroidal anti-inflammatory
drugs (NSAIDs) are the most common causes of DHRs
[2, 15–21].
Antibiotics may account for 27–85% of adverse
drug reactions [22]. Prevalence of respiratory symp-
toms induced by NSAIDs was 1.6% in subjects aged
15–20 years [23]. Large studies on the prevalence of
NSAIDs hypersensitivity reactions in children are
lacking [2, 24]. In this position paper, the Italian
Pediatric Society for Allergy and Immunology (Società
Italiana Allergologia Immunologia Pediatrica –SIAIP)
provides a practical guide for provocation test to anti-
biotics and NSAIDs in children and adolescents.
Drug provocation test in children
A drug provocation test (DPT) is the gold standard to
diagnose DHR with specific indications, limitations and
contraindications that are summarised in Table 1 [6, 25].
The aim of DPT is to evaluate the tolerance to the sus-
pected drug and when negative, to reassure parents that
the drug can be used safely. False-negative provocation
tests can be due to low dosage, short duration or lack of
cofactors (e.g. concomitant infections). False positive
provocation tests can be due to elicitation of subjective
symptoms only.
A single or double-blind DPT using as placebo,
inert substances such as talcum powder or methylcel-
lulose inside opaque jelly capsules is necessary in pa-
tients reporting only subjective or doubtful symptoms
and in those with a history of multiple drug intoler-
ance [26]. DPT with the culprit drug is not recom-
mended in patients with history of severe immediate
or delayed reactions (Table 1).
DPT should always be supervised by personnel trained
to promptly recognize and treat acute allergic reactions
including anaphylaxis [27, 28]. It should be conducted in
a setting with adequate facilities for continuous monitor-
ing of the patient condition and with emergency treat-
ment available. Patients must be healthy. Concurrent
diseases may interfere with interpretation of DPT and
increase the risk of a serious reaction. (Table 1).
Medications that may affect the DPT such as oral
antihistamines, systemic corticosteroids, short-acting
beta2-agonists, ipratropium bromide should be discon-
tinued [25, 27]. Administration of drugs for asthma con-
trol such as inhaled corticosteroids, long-acting
beta2-agonists, leukotriene antagonists, chromones and
theophylline may be continued. A fasting period of 2–4
h prior to the DPT may be considered. At baseline, vital
signs (respiratory rate, heart rate, blood pressure) should
be obtained and physical findings should be recorded to
help as reference. Insertion of an intravenous line should
be considered. Lung function tests may be performed
prior to DPT when necessary, especially in asthmatics
[27, 28].
Betalactams
Hypersensitivity to betalactams, mostly amoxicillin-clavulanic
acid, is suspected in 1.5–12% of children, while
third-generation cephalosporins are less frequently
involved [29]. A study of 2,375,424 children and adults in
Southern California, showed that prevalence of allergy to
penicillin was 7.9% [30]. The diagnostic work-up for beta-
lactams usually shows that the prevalence and incidence
Table 1 Precautions, indications and contraindications of DPT
Contraindications • SCAR, Serum Sickness-Like Reactions, internal organ or system involvement.
• Availability of alternative drugs, the drug will be probably not used in the future.
• Suggestive clinical history, positive allergy tests.
• Active disease such as uncontrolled asthma, urticaria, intercurrent infections, severe allergic
rhinitis. Conditions that may affect treatment of allergic reactions, such as cardiovascular
disease, treatment with β-blockers.
Precautions • The risk/benefit balance must be discussed with patient and caregivers in children with
anaphylaxis.
Indications • Mild reactions.
• Suggestive clinical history with negative or unavailable allergy tests.
• Clinical history not suggestive and/or non-specific symptoms.
• To exclude cross-reactivity with related drugs in subjects with known drug reaction.
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of hypersensitivity reactions to betalactams are overesti-
mated [2]. A high negative predictive value of 94% of beta
lactam DPT has been found [2, 31]. In a large study in-
volving both children and adults [31] most of the reactions
elicited by DPT were mild, non-immediate and cutaneous
(urticaria or rash).
The administration of alternative betalactam drugs in
people who have already experienced an allergic reaction
to a drug of the same class is a key issue. Cross-reactions
between penicillins and cephalosporins is reported in less
than 10% of patients allergic to penicillins and mainly de-
pends on the molecular structure of the side chain placed
in position − 7 of the betalactam ring [32, 33]. The prob-
ability of cross-reaction decreases from the first gener-
ation cephalosporins to the third-generation that appear
to be at low risk of cross-reactions [34–38]. Reactions to
penicillins in patients allergic to cephalosporins have been
sparsely investigated. Less than 20% of cephalosporin al-
lergic patients showed positive skin tests to penicillins,
mostly due to cross reactivity with cephalosporins with a
similar side chain [29, 39]. DPT helps also to exclude
cross-reactivity between drugs belonging to the same
class, as it happens for cephalosporins. Some reactions are
directed towards specific determinants of the lateral chain
R1 of cephalosporins. Therefore, allergic patients can tol-
erate cephalosporins with a different R1 side chain [40].
Cross-reactivity between penicillins or cephalosporins
with other betalactams is rare [41].
It is recommended to perform the diagnostic work-up
for betalactams reactions 1–6 months after the allergic
reaction because afterwards the tests may become nega-
tive. In vivo tests, skin prick tests (SPT) and intradermal
skin test (ID) to minor determinant mixture (MDM),
benzyl penicilloyl-polylysine (PPL), ampicillin, benzylpe-
nicillin, amoxicillin, cephalosporins are validated and
their negative predictive value is high for immediate re-
actions [42]. SPT and ID for clavulanic acid are reported
to be positive in 30% of adults who reacted to amoxicla-
vulanate [43]. Their diagnostic accuracy is limited by the
difficulty of having a stable solution of clavulanic acid
suitable for in vivo or in vitro testing [44]. Detection of
serum-specific IgE in vitro is available for penicillin G,
penicillin V, amoxicillin, ampicillin and cefaclor. The
sensitivity of these tests depends on the antigen, on the
time interval between reaction and IgE measurement
and on the clinical reaction. When IgE tests are negative,
a DPT should be performed according to the criteria dis-
played in Table 1. In case of immediate reactions to
beta-lactams that occurred more than 6months before a
negative DPT, another drug challenge may be performed
after 2–3 weeks, to exclude a possible re-sensitization.
Performing SPT/IgE tests before a re-challenge, may be
considered. The rate of positive rechallenge varies from
2% in children to 23% in studies on adults and children
[45–47]. In non-immediate reactions, delayed-reading
ID, SPT and patch tests can be used with low sensitivity,
as reported in the diagnosis of mild delayed cutaneous
reactions [2, 48–50]. Therefore, in mild cutaneous de-
layed reactions, it is suggested to perform only DPT [2,
48, 49] because of its high negative predictive value [50,
51], without skin testing and serum IgE measurement.
DPT in immediate reactions
There is no standardized protocol for DPT in children
with immediate reactions or when the time interval be-
tween reaction and exposure to the drug is unclear. Di-
vided incremental doses of the single therapeutic dose
are usually administered in a multistep provocation test.
Determining the initial dose depends mainly on clinical
history and the probability of true drug allergy [26]. It
has been reported that patients is associated with a
lower risk for development of a severe acute reaction to
the drug may be challenged with a higher starting dose
[26]. DPT is usually started with 1/100 or 1/10 of the
single therapeutic dose calculated for the weight and the
age of the child. The European Network on Drug allergy
(ENDA) Task Force [2] recommends starting at 1/10 of
the dose and then administering half and the full dose.
In the event of severe reactions, the initial dose is de-
bated. Some European authors suggest starting with
1:10000 or 1:1000 of the maximum therapeutic dose and
then administering increasing doses until the maximum
single therapeutic dose is reached [49]. A recent study
by Chiriac and colleagues [52] have suggested a new
protocol for DPT to beta-lactams based on the analysis
of 182 positive challenge tests. They administered four
doses, containing 5-15-30-50% of the single therapeutic
dose, with additional steps in case of anaphylaxis. There-
fore, a 1 day protocol was appropriate for immediate
mild reaction or delayed mild reaction. Patients should
be kept under surveillance for 2 h after administration of
the last dose and for additional 48 h after discharge. The
time interval between doses should be based on clinical
history and it can vary from 20min to 1 week. Generally,
an interval of 20 to 60min between each dose is consid-
ered appropriate for patients with a history of immediate
reactions. Longer time intervals have been suggested for
non-immediate reactions [29]. A protocol with 3 or
more steps has not been approved in the United States
suspecting that an unintentional desensitization can be
induced [2]. Furthermore, a DPT in three or more steps
are more expensive and time-consuming while severity
and frequency of reactions are comparable to those oc-
curring in a single-dose or two-dose provocation tests
[26]. If an immediate hypersensitivity reaction occurs
during DPT and alternative drugs are unavailable, a
desensitization protocol should be considered.
Caffarelli et al. Italian Journal of Pediatrics          (2018) 44:147 Page 3 of 10
DPT in delayed reactions
The methods of provocation test in case of delayed reac-
tions are widely debated and an international consensus
is still lacking. In Europe, DPT aims to confirm or ex-
clude the diagnosis of hypersensitivity to beta-lactams
while in United States, it aims to exclude the diagnosis
of hypersensitivity in low-risk cases [53]. Therefore, the
protocols of DPT in United States and Europe are differ-
ent. There is difference of opinion on the administration
of divided increasing doses or a single dose [54]. Fur-
thermore, although it is recognized that administering
the daily therapeutic dose for 3 to 7 consecutive days re-
duces the risk for future reactions, members of the
ENDA Task Force [2] and some American authors [54]
believe that exposure to a single therapeutic dose is
enough to reach the diagnosis in most of the cases [2].
However, the rate of subjects with positive DPT was
higher in patients who continued to take the drug for at
least 3–5 days at home than in those who did not [15,
55–59]. Reactions reported after an extended DPT at
home have been found to be mild [60]. More studies are
necessary to assess risks/benefits of a prolonged DPT in
terms of sensitivity, cost and adherence.
Betalactam provocation test protocol
- Immediate reactions (Table 2). A DPT involves admin-
istering 1/10 or 1/100 of the single therapeutic dose then
2/10 and 7/10 every 30min with a minimum of
two-hours surveillance after the last dose. Administra-
tion of an additional single full dose of the drug the
same day or the next day may be considered [2]. Patient
should be contacted 48 h after discharge, because the
elimination of the drug requires this duration, and de-
layed reactions due to anamnestic errors may occur [50].
- Delayed reactions. Incremental doses as those ad-
ministered in DPT for immediate reactions, or a single
dose are given on the first day under physician supervi-
sion [2]. The test is continued at home and the thera-
peutic dose is taken once or twice a day for a minimum
of 5 days (up to 7 days) to elicit the T cell response [55].
Alternatively, a single therapeutic dose is given at the of-
fice, with a surveillance period of 2–5 days at home. The
patient is asked to contact the physician to communicate
the outcome of the test [61]. If any reaction occurs at
home, the patient must be re-examined.
Non-betalactam antibiotics
The prevalence of allergic reactions to non-betalactam
antibiotics (NBLA) is estimated to be 1–3% of the gen-
eral population and represents about 10% of DHRs in
children [62]. Viral infections can provoke skin erup-
tions such as macular exanthemas that is also the most
common symptom of allergic reactions to NBLAs.
Therefore, it is difficult to differentiate DHRs from skin
symptoms due to infections.
The main classes involved in DHRs in children are sul-
phonamides, macrolides, glycopeptides, aminoglycosides
and quinolones. Reactions to tetracycline, metronidazole,
nitrofurantoin antituberculosis drugs have not been as-
sociated with an immunologic mechanism and the diag-
nostic value of allergy tests is unclear [1, 63].
We summarized below the current knowledge on
hypersensitivity reactions to specific NBLA although
specific studies are scarce.
Sulphonamides
It is recommended to perform the diagnostic work-up
for sulphonamides within 1–6 months of the reaction
[64]. In vivo test may be useful: SPT and
immediate-reading ID for IgE-mediated reactions and
delayed-reading ID for delayed reactions. Sensitivity of
these tests is low, but the specificity is high [63]. DPT
represents the diagnostic gold standard and the most re-
quired test in HIV + patients who often need prolonged
therapies with this drug, not easily replaceable, for pre-
venting opportunistic infections. In case of mild or mod-
erate non immediate reactions (without mucosal signs
or systemic symptoms) different strategies have been
proposed. It is possible to continue cotrimoxazole ad-
ministration at the same doses (treat through) or to dis-
continue the drug over a few months, usually 6 months,
and then cotrimoxazole could be resumed after a graded
challenge or a “desensitization” protocol [62]. A
meta-analysis involving 268 adults with HIV infection
and mild or moderate hypersensitivity reactions to cotri-
moxazole found that the desensitization protocol was
Table 2 Betalactam provocation test
Symptoms Procedures
Immediate reactions with negative skin tests Graded challenge
1/10 TD (1/100 TD or 1/1000 TD when risk is high, e.g. severe asthma)
then 2/10 TD and 7/10 TD every 30min
2 h observation after last dose
Delayed reactions Graded challenge as DPT for immediate reactions, or a full-dose challenge.
The daily therapeutic dose is given at home for a minimum of 5 days up to 7 days.
Positive skin tests Anaphylaxis Desensitization
TD therapeutic dose
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the most beneficial for preventing severe skin reactions,
when it is performed after 6 months of drug discontinu-
ation [65].
Macrolides
Hypersensitivity reactions to macrolides are relatively
uncommon (0.4 to 3% of treatments) [66]. Diagnostic
workup for macrolides is hampered by the poor
standardization of skin tests as well as by lack of ac-
curate in vitro tests. Few studies, most of which in
adult population, report a rate of positive skin tests
for macrolides ranging from 28 to 43%. The sensitiv-
ity and specificity of IDs to clarithromycin at the con-
centration of 0.5 mg/ml are reported to be 75 and
90%, respectively [67]. In children, little data exists on
non-irritant concentrations [68]. Therefore, a positive
skin tests to macrolides is open to ambiguous inter-
pretation [69]. There is also limited evidence on the
usefulness of patch tests and delayed-reading IDs
[67]. Thus, DPT is the only reliable diagnostic test
[70], even in the absence of standardized protocol
specific for macrolides. Macrolides can be adminis-
tered orally or iv, but the oral route is considered
safer in case of immediate reactions. The most com-
mon method for performing DPT is the graded chal-
lenge. Patients with a history of delayed reactions
should continue to take the drug at therapeutic doses
for at least 5 days [71].
Glycopeptides
There are no validated in vitro tests for investigating al-
lergy to glycopeptide. In patients with suggestive clinical
history, positive immediate-reading IDs (0.1 mg/ml or
lower) may identify immediate hypersensitivity reactions,
and positive patch tests (concentration 0.005%) delayed
hypersensitivity reactions [63]. In patients with history
of mild reaction, a graded challenge should be per-
formed [72]. Despite its chemical affinity, no cases of
Red Man Syndrome and very few cases of allergic reac-
tions were reported with teicoplanin [73] in children
with previous reactions to vancomycin. Thus, in these
children, teicoplanin might be administered even if there
is limited evidence that is tolerated [63]. When possible,
an alternative drug should be used or a desensitization
protocol should be performed.
Aminoglycosides
Although anecdotal cases of positive SPT to tobramycin,
gentamicin, and streptomycin [74] have been observed,
in vivo tests are not validated for the diagnosis of imme-
diate reactions to aminoglycosides. Moreover, it has been
reported that SPT to streptomycin has triggered a sys-
temic reaction [75]. Patch tests with reading at 72 and
96 h have been performed for the diagnosis of
non-immediate reactions [76, 77] In vitro tests are not
validated. Since aminoglycosides are given by injection,
the intravenous route is used for DPT. A graded chal-
lenge should be performed only in children with sus-
pected immediate mild reactions. Cross-reactivity
between aminoglycosides is common (50%) [1, 78].
Quinolones
SPT and ID are not recommended for the diagnosis
of hypersensitivity to quinolones because they can in-
duce direct mast cells activation, leading to false posi-
tive results [1, 79]. Moreover, controversy exists on
non-irritant concentrations for skin [1, 79]. In the
diagnosis of delayed reactions, patch test has provided
inconsistent results [66]. DPT remains the reference
standard for the diagnosis even if not without risk
[80]. A multidose challenge or a full dose challenge is
recommended depending on the clinical risk (Table 3).
Cross-reactivity is common between first and
second-generation quinolones, less common between
first or second generation and third and fourth gener-
ation quinolones. Cross-reactions between quinolones
and neuromuscular blocking agents have been also
described [81].
DPT to non-betalactam
For NBLAs, specific-IgE measurement methods are
not available and other in vitro tests such as basophil
activation test (BAT), lymphocyte transformation test
(LTT) and ELISPOT test are not routinely used. Fur-
thermore, false positive skin test may occur because
nonirritating concentrations are established in adults
but not in children [63]. On the other hand, a nega-
tive skin test does not exclude the occurrence of an
allergic reaction [79]. Despite these limitations, in
children with positive NBLA skin test associated with
a suggestive history of allergic reaction, the use of al-
ternative antibiotics is recommended. When no alter-
native antibiotics are available, it is necessary to
perform a desensitization [54]. DPT method for
NBLA should be based on history and skin tests re-
sults (Table 3) [54]. A multidose drug challenge is
typically used in children with history of immediate,
undefined or delayed reactions. Doses are given orally
if possible. It is performed by dividing the therapeutic
dose in increasing doses until a single therapeutic
dose is obtained. It is generally sufficient to adminis-
ter 2–3 doses and they can be further divided [4, 5]
in case of high risk of reaction. It is suggested not to
exceed 5 doses to prevent an unintentional patient
desensitization. In patients with mild reaction, a full
dose challenge can be performed [54]. In patients with
mild/moderate reactions, the starting dose is 1/10 of the
therapeutic dose followed by incremental doses (Table 3)
Caffarelli et al. Italian Journal of Pediatrics          (2018) 44:147 Page 5 of 10
or by a full dose [54]. In patients at high-risk because of
comorbid disease (e.g. severe asthma), it is suggested to
start with 1/100 (or 1/1000) of the therapeutic dose
followed by 1/10 and then by incremental doses (Table 3)
or a full dose [54]. Doses are commonly given every 30
min, but some authors have recommended a time interval
of 1 h [54, 78]. After the last dose, the patient should be
monitored for 2–4 h [54]. In children with
non-immediate reactions, the drug should be continued
at home for 3–5 days and the patient should be
instructed to return immediately to the hospital if a de-
layed clinical reaction occurs [54].
Non-steroidal anti-inflammatory drugs (NSAIDs)
Ibuprofen, paracetamol and pyrazolones are the most
common NSAIDs involved in hypersensitivity reactions
[82–84]. NSAIDs can induce both allergic hypersensitivity
reactions mediated by an immunological mechanism, i.e.
IgE mediated, T-lymphocyte mediated, and non-allergic
hypersensitivity reaction initiated by non-immunological
mechanisms [24, 27, 77].
Cross-intolerance hypersensitivity reactions to NSAIDs
are more frequent and include NSAIDs-Exacerbated Re-
spiratory Disease (NERD), NSAIDs-exacerbated cutane-
ous disease (NECD) (e.g. urticaria), NSAID-induced
urticaria-angioedema (NIUA) [27]. They occur up to 6 h
after NSAID intake. These reactions are due to a
non-immunologic mechanism related to the COX-1 inhi-
biting properties of the drug that reduces the synthesis of
prostaglandins (PG) and thromboxanes, increases the pro-
duction of leukotrienes (LTs) and induces an overexpres-
sion of LTC4 synthase (terminal enzyme for the
production of cys-LTs). Although there are two known
COX isoenzymes, COX-1 and COX-2, any NSAID that in-
hibits COX-1, even if belonging to a different class, in-
cluding aspirin may elicit reaction in susceptible
individuals (‘cross-intolerants’) [27, 85]. COX-3, a splice
variant of COX-1, has been suggested to be the site of ac-
tion of paracetamol. This could explain why paracetamol
has fewer side effects and less cross-reactions with
NSAIDs than other COX inhibitors [86].
Selective hypersensitivity reactions to NSAIDs [27] are
triggered by a single drug and they rarely may be elicited
by more than one NSAID belonging to the same subclass.
Other subclasses are tolerated. They include Selective
NSAID-induced urticaria, angioedema, and/or anaphylaxis
(SNIUAA) and Selective NSAID-induced delayed type
hypersensitivity reactions (SNIDR). SNIUAA is probably
IgE-mediated reaction occurring within 1 h of the drug in-
take [85]. Allergic reactions may be of different degrees of
severity: from urticaria/angioedema to anaphylaxis. Patients
with allergic reactions to an NSAID have had generally at
least one prior exposure to the culprit drug, which presum-
ably sensitizes them. Subsequently, the reaction is elicited
by following drug exposure. NSAIDs-induced urticaria/an-
gioedema with/without respiratory and systemic symptoms
of anaphylaxis (NIUAA) has been also described in chil-
dren. Selective NSAID-induced delayed type HS reactions
(SNIRD) includes a spectrum of skin manifestations such
as maculo-papular rash, fixed erythema, contact dermatitis
and photoallergy. Sometimes, fever and involvement of in-
ternal organs may also occur, while SYS, Lyell Syndrome,
and DRESS are rare. These reactions are cell-mediated
(Type IV hypersensitivity) and they typically begin 24–48 h
after drug intake, but occasionally earlier [27, 87].
Diagnostic work-up
The diagnostic work-up should be performed 1–6months
after the reaction, the longer the time between the reac-
tion and the skin tests, the lower the negative predictive
value and higher the risk of false negatives [88].
SPT, ID, patch test, photopatch test are not standard-
ized [27, 89]. SPT to metamizole, dipyrone, and para-
cetamol may be helpful in children with immediate
reactions [27]. However, their sensitivity is low. Diagnos-
tic accuracy of in vitro tests (serum specific IgE, hista-
mine release test and BAT) has not been established and
they are therefore not recommended [27, 90]. Recent
studies investigated on BAT as complementary tool for
the evaluation of DHRs, revealing a high specificity but a
low sensitivity [90]. The diagnostic work-up in DHRs
may be expanded and completed with BAT, because the
concordance of anamnesis and in vitro tests may reduce
the need for challenges, limiting them to selected case-
sThe diagnosis of NSAID allergy is based on the clinical
history and must be confirmed by DPT. DPT is the only
Table 3 Methods of drug provocation test for NBLA
Symptoms Procedures
Mild urticaria or mild skin reactions Full-dose challenge
Mild/moderate urticaria or other skin reactions Negative skin tests Graded challenge
(1/100 TD or 1/1000 TD when risk is high, e.g. severe asthma)
1/10 TD
2/10 TD
7/10 TD
1 h observation after each dose
Positive skin tests Anaphylaxis Desensitization
TD, therapeutic dose
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commonly available tool to identify the causal role of the
suspected drug and it should be performed [86] accord-
ing to the criteria summarized in Table 1. The negative
predictive value of DPT was estimated at about 97.8%
[92]. DPT should be also performed to identify a safe al-
ternative drug in subjects with allergy to NSAID [91].
DPT protocols differ in initial dose and time interval
between doses. An initial administration of 1/10 of the
single therapeutic dose followed by 2/10 and then 7/10
every 60 min has been suggested. Other protocols rec-
ommend dividing the therapeutic dose into 3 equal
doses, each given at one-hour intervals [93] (Table 4). In
patients who have a history of anaphylaxis, the first dose
should be 1/100 or 1/1000 of the total cumulative dose
[92]. ENDA consider more appropriate performing a
multistep challenge, starting with 1/10 of the therapeutic
dose also in patients with history of severe reactions or
suspected IgE mediated reactions [94]. The total cumu-
lative dose should be: paracetamol 15–20 mg/kg/dose,
ibuprofen 10 mg/kg/dose, ASA 15–20mg/kg/dose [27].
A 3-h observation is recommended after the last dose.
In children with history of angioedema, the period of ob-
servation should be at least 6 h. In delayed,
non-immediate reactions (SNIDRs), longer surveillance
period based on history may be necessary. In patients
who have experienced wheezing after exposure to an
NSAID, spirometry should be performed at the begin-
ning of the DPT and 30min after each dose. The test
should be stopped immediately when a drop in FEV1 ≥
20% occurs [93]. When a DPT with the culprit drug, has
a positive outcome, the question arises whether the reac-
tion is immune-mediated. Patients should undergo an
oral challenge to acetylsalycilic acid (ASA) to clarify the
mechanism of the reaction. The risk of Reye’s Syndrome
is virtually absent, when DPT to ASA is performed in
children without infections. A positive DPT indicates
that the reaction is non immune-mediated because ASA
is a specific inhibitor of COX-1 and a COX-2 inhibitor
should be tested [27]. On the other hand, a negative
challenge to ASA indicates that the reaction may be
immune-mediated and a chemically unrelated NSAID
should be tested.
Conclusions
Laboratory tests for identifying children who are allergic
to drugs with high diagnostic accuracy and predictive
value are not yet available. The provocation test is the
gold standard for ascertaining the causative role of an al-
lergen [95, 96], as well as for determining the diagnosis
of drug tolerance. However, DPT is time-consuming, re-
source consuming and may potentially induce serious
reactions. Information provided in this paper do not
eliminate the need of a proper training to perform this
test safely. Therefore, there is an urgent need for the de-
velopment of simple noninvasive markers [97] for drug
allergy in children.
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Table 4 Provocation test to NSAID in children
Drug Dose (mg/kg) Subsequent
doses
Interval between
doses (h)
Maximum dose (mg/kg) Mean reaction time (h)
Kidon MI, 2007
[91]
ASA 2,5 Same dose 1 10 1–4
Ibuprofen 2,5 Same dose 1 10 2–4
Paracetamol 5 Same dose 1 20 2–4
Kidon M, 2018 [27] 1/10–1/4 of the
maximum dose
Incremental
doses
1 - Paracetamol 15–20 mg/kg/
dose,
-Ibuprofen 10 mg/kg/dose,
-ASA 15–20 mg/kg/dose
2–4
Additional doses of the
drug can be necessary
on the following days at
home
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